19例胃食管反流病患者根除幽门螺杆菌后食管酸反流的变化

目的：在胃食管反流病(GRED)患者根除幽门螺杆菌(Hp)是否会加重胃食管反流目前存在很大争议。本研究将采用食管内24h pH监测及食管测压检查的方法，定量观察GERD患者根除Hp治疗前后食管酸暴露及食管动力的变化。方法：连续选取我院门诊就诊的Hp阳性GERD患者。Hp感染诊断依据RUT和UBT或UBT和血清学检查。所有入选对象均在内镜检查后1～3d内行食管内24h pH监测和食管测压检查，同时评估反流症状。给予1周三联根除Hp治疗(奥美拉唑20mg，克拉霉素0．25g，阿莫仙1．0g，均bid)。疗程结束3个月后^14C—UBT检查，证实Hp根除者复查食管内24h pH监测和食管测压，同时重新评估反流症状。随访期间不用抑酸剂及促动力剂。结果：共23例Hp阳性GERD患者入选了本研究，其中19例患者完成了根除Hp前后的对比研究。在入选时有6例患者内镜下表现符合反流性食管炎，24h食管内pH监测提示病理性反流者10例。在确定根除Hp3个月后反酸、腹痛症状明显改善，食管24h pH监测各项参数与根除前相比均无显著性差异。LESP根除前10mm Hg(7．7—15．9)，根除后15mm Hg(10—20．6)，前后相比有显著性差异。食管体蠕动无明显改变。结论：本研究在GERD患者根除Hp3个月后反流症状有改善，食管酸暴露情况无明显变化，LESP较根除前增高，提示在GERD患者根除Hp有可能改善胃食管反流症状。     

胃食管反流病

随着胃食管反流病(GERD)患病率的增加，GERD相关并发症亦有所增加，包括Barrett食管和食管腺癌。过去1年提出的有关GERD病理生理学的新观点有助于我们更好地理解反流性疾病发病和黏膜损伤症状之间的关系，并提供针对病人个体化病理生理缺陷的治疗。     

胃食管反流病与幽门螺杆菌

胃食管反流病(GERD)是指胃、十二指肠内容物反流入食管,引起的烧心、反酸等症状和/或食管组织学损伤的疾病。西方国家的总体人群研究报告,4％～9％的成人每天有烧心感,10％～15％则每星期至少发生一次烧心感。国内相应的流行     

幽门螺杆菌与胃食管反流病

幽门螺杆菌（Helicobacter pylori，H．pylori）与胃食管反流病（gastroesophageal reflux disease，GERD）的关系各研究结果不尽一致，流行病学研究表明，在GERD中不仅Mpylori感染率较低，而且cagA的检出率也低，二者都与食管疾病严重程度呈负相关。亦有文献报告H．pylori感染与GERD发生无明显关系。H．pylori对食管保护作用机制可能与其能提高LES压力、降低胃内酸度和影响食管对酸的敏感性有关。有研究表明，H．pylori可以提高质子泵抑制剂的抑酸效果，亦有人认为H．pylori并不影响GERD疗效。因此H．pylori与GERD的关系仍需进一步的临床和基础研究来评价。     

幽门螺杆菌与胃食管反流病

现有研究报道随着Ｈｐｙｌｏｒｉ感染率的逐渐下降 ,胃食管反流病 (ＧａｓｔｒｏｅｓｏｐｈａｇｅａｌＲｅｆｌｕｘＤｉｓｅａｓｅ ,ＧＥＲＤ)和食管腺癌的发病率却明显上升[1,2 ] ,Ｈｐｙｌｏｒｉ和ＧＥＲＤ的关系已经成为一大研究热点。由于Ｈｐｙｌｏｒｉ主要定居于柱状上皮 ,在食管鳞状上皮不能定植[3,4 ] ,因此ＧＥＲＤ与Ｈｐｙｌｏｒｉ的关系 ,主要是研究其与定居于胃窦或胃体的Ｈｐｙｌｏｒｉ的关系。一、Ｈｐｙｌｏｒｉ对ＧＥＲＤ可能具有保护作用目前文献报道在ＧＥＲＤ中不仅Ｈｐｙｌｏｒｉ感染率较低[5,6 ] ,而且ｃａｇＡ的检出…     

幽门螺杆菌与胃食管反流病关系的研究进展

胃食管反流病(gastroesophageal reflux disease,GERD)指食管黏膜异常地暴露于胃内容物所导致的疾病,包括内镜阴性的胃食管反流、反流性食管炎、Barrett食管及其他并发症.幽门螺杆菌(Helicobacterpylori,Hp)感染在胃炎、消化性溃疡、胃癌和胃MALT淋巴瘤发生发展中的作用已得到公认,目前针对Hp的治疗方案已有明确指南,根除成功率也明显提高.但有研究报道,随Hp感染率的逐渐下降,GERD和食管腺癌的发病率却明显上升.Hp与GERD的关系是目前研究的热点,而对于合并Hp感染的GERD患者是否进行根除治疗仍然是目前争议的论题.     

胃食管反流病与幽门螺杆菌感染相关机制研究进展

近年来,幽门螺杆菌(Helicobacter pylori, H. pylori)在我国的感染率呈下降趋势,但由于人口基数相对大,我国H. pylori感染人数仍较多.许多疾病合并H.pylori感染采取根除治疗,而H. pylori对胃食管反流病(gastroesophageal reflux disease, GERD)的影响存在争议,因此对于H. pylori感染患者是否采取根除治疗尚待商榷. GERD的发病机制与多种因素有关,本文就GERD与H. pylori感染相关机制进行综述,为GERD的治疗提供更多思路.     

幽门螺杆菌与胃食管反流病

胃内幽门螺杆菌（Ｈｐ）感染与胃炎，消化性溃疡甚至胃癌的发生密切相关，近年发现Ｈｐ亦可存在于食管的化生柱状上皮中，研究Ｈｐ感染与胃食管反充病及其并发症（Ｂａｒｒｅｔｔ食管及食管腺癌）的发生，发展之间的关系对胃食反流病的合理治疗有重要的意义。     

胃食管反流病与幽门螺杆菌感染的关系研究

目的:探讨胃食管反流病(GERD)与幽门螺杆菌感染(H.pylori)的关系。方法:将内镜检查确诊的112例GERD患者,按H.pylori检测结果分为H.pylori( )组和H.pylori(-)组,以内镜下食管炎的分级进行严重度比较。H.pylori( )组H.pylori根除后与H.pylori(-)组在半年、1年后进行复发率的比较。结果:H.pylori( )组和H.pylori(-)组GERD重度检出率分别为36.8%(7/19)和63.2%(12/19),差异有显著性。H.pylori( )GERD患者H.pylori根除后半年、1年食管炎总复发率为70.5%与H.pylori(-)组GERD47.0%比较差异有显著性。结论:H.pylori(-)者GERD重,H.pylori( )GERD患者H.pylori根除后1年食管炎复发率较高,H.pylori对GERD可能有保护作用。     

幽门螺杆菌与胃食管反流病和Barrett食管

本文从幽门螺杆菌(Helicobacter pylori,Hp)与胃食管反流病(GERD)和Barrett食管(BE)的流行病学、发生机理、疗效影响等方面阐述了Hp与GERD、BE的关系,介绍了目前仍存在的一些争议,建议进一步开展临床和基础研究以逐步解决这些问题。     

Barrett's食管的诊断进展

Barrett's食管(Barrett's esophagus, BE)是指食管内膜发生化生, 鳞状上皮被柱状上皮取代, 他是食管腺癌最重要的危险因素. 随着食管腺癌在西方国家的发病率迅速升高, BE日益受关注. 过去几年里, BE领域取得显著的进步, 本文主要针对其诊断标准、内镜诊断及新的内镜成像技术等方面作一综述.     

Advances in Barrett's esophagus and esophageal adenocarcinoma

Despite advances in diagnosis and therapy, esophageal adenocarcinoma remains an aggressive and usually lethal tumor. This review focuses on the epidemiology of esophageal adenocarcinoma and its presumed precursor lesion, Barrett's esophagus; the pathogenesis of the cancer; advances in treatment of adenocarcinoma and Barrett's esophagus; and strategies for cancer prevention. Emphasis is placed on recent literature. Although the absolute number of cases of adenocarcinoma in the United States is still small, the incidence of this cancer has increased dramatically in the last 40 years, and adenocarcinoma is now the predominant form of esophageal cancer in this country. Recent evidence suggests that Barrett's esophagus is more prevalent in asymptomatic individuals than previously appreciated. The pathogenesis of Barrett's esophagus is poorly understood. Given that some subjects will have repeated bouts of severe erosive esophagitis and never develop Barrett's esophagus, host factors must play an important role. The utility of neoadjuvant radiation and chemotherapy in those with adenocarcinoma, although they are widely practiced, is not of clear benefit, and some authorities recommend against it. Ablative therapies, as well as endoscopic mucosal resection, hold promise for those with superficial cancer or high-grade dysplasia. Most series using these modalities feature relatively short follow-up, and longer-term data will be necessary to better describe the effects of these therapies. The value of chemoprevention in subjects with dysplastic Barrett's esophagus by use of cyclooxygenase 2 inhibitors, nonsteroidal anti-inflammatory drugs, or proton pump inhibitors is unknown. Similarly, although endoscopic screening is widely practiced, its value in patients with chronic gastroesophageal reflux disease symptoms is of unproven value, and recommending bodies are divided as to its practice.     

Advances in endoscopic diagnosis and treatment of Barrett's esophagus

Barrett's esophagus (BE) is defined as abnormal specialized columnar metaplasia with intestinalization in place of the normal squamous esophageal epithelium. Gastroesophageal reflux disease is a known risk factor for BE; nonetheless BE is also detected in asymptomatic individuals. Other risk factors for BE include smoking, male gender, age over 50 and obesity. Patients diagnosed with BE (without dysplasia) are recommended to undergo endoscopic surveillance every 3-5 years. Advances in imaging techniques (such as narrow band imaging, autofluorescence imaging and confocal laser endomicroscopy) have the potential to improve the detection of dysplasia and early cancer, thus making surveillance a more cost-effective endeavor. Patients with high grade dysplasia (HGD) and early cancer have a high rate of progression to invasive adenocarcinoma and traditionally these patients were treated with esophagectomy. The rapid advancement of endoscopic therapeutic techniques along with a low risk of complications have made endoscopic therapy an acceptable alternative to an esophagectomy in patients with HGD and early cancer. Several endoscopic treatment techniques such as endoscopic mucosal resection, multipolar electrocoagulation, photodynamic therapy, argon plasma coagulation, cryotherapy, and radiofrequency ablation have been studied for endoscopic treatment.     

Current status of Barrett's esophagus research in Asia

In Western countries, the epidemiology of esophageal cancer has changed considerably over the past decades with a rise in the ratio of adenocarcinoma to squamous cell carcinoma. Although the prevalence of gastroesophageal reflux is increasing in Asia, the prevalences of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC) have remained low in most Asian countries. The Asian Barrett's Consortium recently conducted a review of published studies on BE from Asia to assess the current status of BE research in Asia, and to recommend potential areas for future BE research in the region. Differences in study design, enrolled population, and endoscopic biopsy protocols used have led to substantial variability in the reported BE prevalence (0.06% to 19.9%) across Asia. In particular, some Japanese studies used diagnostic criteria that differed considerably from what was used in most Asian studies. As in Western countries, increased age, male sex, tobacco smoking, reflux symptoms, and erosive esophagitis have been found to be risk factors for BE in several case-control studies from Asia. The Prague C and M criteria, developed to provide better interobserver reliability in diagnosis and grading of BE, are currently under extensive evaluation in the Asian population. There is a need for standardized protocols for endoscopic and histopathologic diagnosis before initiating collaborative projects to identify etiologic determinants of BE and its ensuing malignant transformation. At present, data regarding the management and long-term outcome of BE are extremely limited in Asia. More studies of BE in this geographic area are warranted.     

Barrett's esophagus

Barrett's oesophagus is a premalignant metaplastic change of the oesophageal mucosa. Due to its relationship with oesophageal reflux disease and the development of adenoma-carcinoma of the oesophagus the problem arouses increasing interest. In the wide pathogenesis of the disease most probably the composite effect of the refluxed HCl content and duodenal juices play a part. In the diagnosis in addition to fundamental methods--endoscopy and histology--increasingly chromoendoscopy and fluorescent endoscopy are involved. Dispensarization of patients is essential and depends on the degree of pathohistological epithelial changes. Treatment of Barrett's oesophagus can be divided into conservative, where the drug of choice are proton pump inhibitors, and surgical treatment. Promising is endoscopic ablation of the epithelium in combination with subsequent antisecretory therapy.     

Barrett's esophagus

Barrett's esophagus is an acquired condition resulting from severe esophageal mucosal injury. It still remains unclear why some patients with gastroesophageal reflux disease develop Barrett's esophagus whereas others do not. The diagnosis of Barrett's esophagus is established if the squamocolumnar junction is displaced proximal to the gastroesophageal junction and if intestinal metaplasia is detected by biopsy. Despite this seemingly simple definition, diagnostic inconsistencies remain a problem, especially in distinguishing short segment Barrett's esophagus from intestinal metaplasia of the gastric cardia. Barrett's esophagus would be of little importance were it not for its well-recognized association with adenocarcinoma of the esophagus. The incidence of esophageal adenocarcinoma continues to increase and the 5-year survival rate for this cancer remains dismal. However, cancer risk for a given patient with Barrett's esophagus is lower than previously estimated. Current strategies for improved survival in patients with esophageal adenocarcinoma focus on cancer detection at an early and potentially curable stage. This can be accomplished either by screening more patients for Barrett's esophagus or with endoscopic surveillance of patients with known Barrett's esophagus. Current screening and surveillance strategies are inherently expensive and inefficient. New techniques to improve the efficiency of cancer surveillance are evolving rapidly and hold the promise to change clinical practice in the future. Treatment options include aggressive acid suppression, antireflux surgery, chemoprevention, and ablation therapy, but there is still no clear consensus on the optimal treatment for these patients.     

Barrett's esophagus

Barrett's esophagus is an acquired metaplastic abnormality in which the normal stratified squamous epithelium lining of the esophagus is replaced by an intestinal-like columnar epithelium. While in itself a benign and asymptomatic disorder, the clinical importance of this relatively common condition relates to its role as a precursor lesion to esophageal adenocarcinoma, the incidence of which has dramatically increased in Western populations in recent years. Although known to arise as a consequence of chronic gastroesophageal reflux, the cellular and molecular mechanisms underlying development Barrett's esophagus and its progression to cancer remain unclear.